Alnylam Pharmaceuticals (NASDAQ:ALNY) First Quarter 2023 Results
Key Financial Results
Revenue: US$319.3m (up 50% from 1Q 2022).
Net loss: US$174.1m (loss narrowed by 28% from 1Q 2022).
US$1.40 loss per share (improved from US$2.00 loss in 1Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Alnylam Pharmaceuticals Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 19%.
Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.
The company's shares are up 4.8% from a week ago.
We should say that we've discovered 3 warning signs for Alnylam Pharmaceuticals (1 is a bit unpleasant!) that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here